Evidence map›Paper›PMID 26353868›Full record

ArticleBMJ open2015

Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: study protocol for a systematic review and network meta-analysis.

Xinyu Zhou, Bin Qin, Craig Whittington, David Cohen, Yiyun Liu, Cinzia Del Giovane, Kurt D Michael, Yuqing Zhang, Peng Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinyu ZhouDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Bin QinDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Craig WhittingtonResearch Department of Clinical, Educational and Health Psychology, University College London, London, UK.
David CohenDepartment of Child and Adolescent Psychiatry, AP-HP, Hôpital Pitié-Salpétrière, Institut des Systèmes Intelligents et de Robotiques (ISIR), Centre National pour la Recherche Scientifique, Université Pierre et Marie Curie, Paris, France.
Yiyun LiuDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Cinzia Del GiovaneDepartment of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio, Emilia, Modena, Italy.
Kurt D MichaelDepartment of Psychology, Appalachian State University, Boone, North Carolina, USA.
Yuqing ZhangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Peng XieDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDepressive disorders are among the most common psychiatric disorders in children and adolescents, and have adverse effects on their psychosocial functioning. Questions concerning the efficacy and safety of antidepressant medications in the treatment of depression in children and adolescents, led us to integrate the direct and indirect evidence using network meta-analysis to create hierarchies of these drugs. METHODS AND ANALYSIS: Seven databases with PubMed, EMBASE, the Cochrane Library, Web of Science, CINAHL, LiLACS and PsycINFO will be searched from 1966 to December 2013 (updated to May, 2015). There are no restrictions on language or type of publication. Randomised clinical trials assessing first-generation and newer-generation antidepressant medications against active comparator or placebo as acute treatment for depressive disorders in children and adolescents (under 18 years of age) will be included. The primary outcome for efficacy will be mean improvement in depressive symptoms, as measured by the mean change score of a depression rating scale from baseline to post-treatment. The tolerability of treatment will be defined as side effect discontinuation, as defined by the proportion of patients who discontinued treatment due to adverse events during the trial. We will also assess the secondary outcome for efficacy (response rate), acceptability (all-cause discontinuation) and suicide-related outcomes. We will perform the Bayesian network meta-analyses for all relative outcome measures. Subgroup analyses and sensitivity analyses will be conducted to assess the robustness of the findings. DISSEMINATION: The network meta-analysis will provide useful information on antidepressant treatment for child and adolescent depression. The results will be disseminated through peer-reviewed publication or conference presentations. TRIAL REGISTRATION NUMBER: PROSPERO CRD42015016023.

Indexed as

Drug ToleranceAdolescentAntidepressive AgentsChildDepressive DisorderHumansMeta-Analysis as TopicPsychiatric Status Rating ScalesSystematic Reviews as TopicTreatment OutcomeAntidepressive AgentsCLINICAL PHARMACOLOGY

Identifiers

PMID26353868
PMCPMC4567669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.